English Global
US delegation led by Ambassador to India, Mr. Eric Garcetti; Ms. Loyce Pace, Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS) and Ms. Genessa Giorgi, Health Attaché, HHS visited Panacea Biotec R&D Centre, Developing Novel Tetravalent Dengue Vaccine “DengiAll”
From Left to Right: Mr. Ankesh Jain, Director-Sales & Marketing, Panacea Biotec; Dr. Rajesh Jain, Chairman & Managing Director, Panacea Biotec; Ms. Loyce Pace, Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS); Mr. Eric Garcetti, U.S. Ambassador to India; Mr. PD Karan, Sr. Vice President, Panacea Biotec at the R&D Centre of Panacea Biotec, New Delhi
Mr. Eric Garcetti, U.S. Ambassador to India and Ms. Loyce Pace, Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS) were thrilled holding world’s 1st tetravalent DengiALL vaccine vials at Panacea Biotec R&D Facility in New Delhi
Press Note: US delegation led by U.S. Ambassador to India, Eric Garcetti (2nd from the left) and Ms. Loyce Pace; Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS) visited Panacea Biotec, India’s leading biotechnology company’s advanced research and development centre at New Delhi on August 21 and were impressed with the path breaking research and development work carried out by Panacea Biotec and how DengiAll, Dengue vaccine is being developed. Other dignitaries in the delegation included Ms. Genessa Giorgi, HHS Health Attaché,; Ms. Nandita Chopra, NIAID Representative, India; Dr. Shweta Aggarwal, NIAID Scientific Affairs and Dr. Syed Asrafuzzaman, HHS Scientific Affairs Specialist.
Speaking on the occasion, Dr. Rajesh Jain, Chairman & Managing Director, said “Panacea Biotec is committed to develop vaccines to meet the unmet demands of global community. Development of DengiAll vaccine in close collaboration with NIAID/NIH, US, Indian Council of Medical Research (ICMR), New Delhi and Ministry of Health and Family Welfare, Government of India is a step in this direction.
We are extremely thankful to NIH especially to Dr. Steve Whitehead, Dr. Anna P. Durbin from Johns Hopkins Bloomberg School of Public Health, of supporting the entire Dengue Vaccine development program being flexible, making all resources available swiftly.
The entire team at our Research Centre One Stream and Senior Management are deeply touched and thankful to:
for having chosen to visit Panacea Biotec Research Centre during their visit to India and importance shown to work being done at our Research Centre.
We are extremely thankful to Government of India, Ministry of Health and Family Welfare, Indian Council of Medical Research, Drug Controller General of India, Central Drug Laboratory, Kasauli for supporting the development of Dengue vaccine and seeing value in our work for the collective good of the world.
“One Earth One Family Save Earth.”
Mr. Eric Garcetti, U.S. Ambassador to India, said, ”We’re proud to support efforts like the DengiAll initiative to take action against a disease that each year claims the lives of tens of thousands and threatens the well-being of hundreds of millions. Vaccines like this hold the potential to improve health outcomes on a global scale, showing the power of U.S.-India partnership to build a safer and more prosperous world.
Ms. Loyce Pace, Assistant Secretary for Global Affairs, HHS, said, “Vaccine development is an important pillar of our health partnership with India. Together we can address the largest global health challenges of the world.”
DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research and development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies. Panacea Biotec through continued support from National Institutes of Health, Technology Development Board, and other stakeholders is in a better position to increase affordable access to DengiAll to fight Dengue, a disease that has eluded mankind for generations. With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion.
Panacea Biotec is expected to start its Phase 3 Clinical Trials soon post receiving approval from Drug Controller General of India (DCGI) and Central Drug Laboratory (CDL), Kasauli a single-dose live-attenuated tetravalent vaccine to meet the unmet demands of millions of patients suffering from Dengue every year world over.
About Dengue
Dengue is the fastest spreading mosquito-borne viral disease and is one of the World Health Organization’s top 10 threats to global health in 2019. Dengue is mainly spread by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus mosquitoes. It is caused by any of four Dengue virus serotypes, each of which can cause Dengue fever or severe Dengue.The prevalence of individual serotypes varies across different geographies, countries, regions, seasons and over time.Recovery from infection by one serotype provides immunity against only that serotype, and later exposure to any of the remaining serotypes is associated with an increased risk of severe disease.
According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and it is critical that we have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions.
Dengue is pandemic prone, and outbreaks are observed in tropical and sub-tropical areas and have recently caused outbreaks in parts of the continental U.S. and Europe.Approximately half of the world now lives under the threat of Dengue, which is estimated to cause 390 million infections and more than 20,000 deaths globally each year.The Dengue virus can infect people of all ages and is a leading cause of serious illness among children in some countries in Latin America and Asia.1
U.S. Ambassador to India Eric Garcetti (2nd from the left); Ms. Loyce Pace; Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS) – (1st from the left); Dr. Rajesh Jain, Chairman & Managing Director, Panacea Biotec (3rd from the left); Mr. Ankesh Jain, Director, Sales and Marketing, Panacea Biotec (2nd from the right); Dr. Amulya Panda, Associate Director, Panacea Biotec (1st from the right) discussing DengiAll vaccine project development through collaboration with National Institute of Health( NIH), USA
Mr. Eric Garcetti, U.S. Ambassador to India and Ms. Loyce Pace, Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS) were extremely impressed during their visit to the hi-tech Research & Development Centre of Panacea Biotec involved in Dengue vaccine research & development on August 21, 2023 at New Delhi
U.S. Ambassador to India, Eric Garcetti; Ms. Loyce Pace; Assistant Secretary for Global Affairs at the Department of Health and Human Services (HHS); Dr. Rajesh Jain, Chairman & Managing Director, Panacea Biotec, Mr. Ankesh Jain, Director, Sales and Marketing, Panacea Biotec, Dr. Amulya Panda, Associate Director, Ms. Genessa Giorgi; Health Attaché, NIAID & Representative to South Asia; Ms. Nandita Chopra, Scientific Affairs Specialist for the National Institutes of Allergy and Infectious Diseases (NIAID/NIH) to India and Rest of Asia; Ms. Shweta Aggarwal, Scientific Affairs Specialist for the National Institutes of Allergy and Infectious Diseases (NIAID/NIH) and Dr. Syed Asrafuzzaman, HHS Scientific Affairs Specialist and Scientists of Senior officials of Panacea Biotec at Panacea Biotec’s R&D Centre at New Delhi
Panacea Biotec’s Commitment to Vaccines
Vaccines prevent 2 to 3 million deaths each year and have transformed global public health.[1] For the past 30 years, Panacea Biotec has supplied vaccines to protect the health of people across the world; it has a strong track-record of supplying more than 10 billion doses of Polio vaccines and over 150 million doses of Innovative fully-liquid wP based Pentavalent and Hexavalent vaccines to national governments, UN Agencies, etc. Panacea Biotec’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as Dengue. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.
About Panacea Biotec
Panacea Biotec is an innovation-led biotechnology group that focuses on discovery, development, and commercialisation of Vaccines, Nutrition and prescription medicines primarily, diabetes, transplant, gastroenterology, and oncology. Its vaccine manufacturing facilities are WHO Prequalified, pharmaceutical and sterile injectable facilities are US FDA approved and all facilities are cGMP compliant. Panacea Biotec launched the world’s first fully-liquid Hexavalent vaccine (DTwP-Hib-HepB-IPV), EasySix in 2017. It is also undertaking developing Pneumococcal Conjugate vaccine among other differentiated Vaccines and drug development programs. Panacea Biotec remains focused on merging cutting-edge science and technology with an unwavering commitment towards unmet medical needs with affordability.
For more information, visit: www.panaceabiotec.com
Panacea Biotec: For Investors
Mr. Devender Gupta
Chief Financial Officer and Head Information Technology
Tel: + 91-11-41679000 Ext. 1225, 41578011 (Direct)
Email: devendergupta@panaceabiotec.com
Panacea Biotec: For Media
Mr. P. D. Karan
Sr. Vice President - Business Development & Corporate Affairs
Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)
Mobile: + 91 9312693040
Email: pdkaran@panaceabiotec.com